Loading…

Steroid-resistant autoimmune myelofibrosis in a patient with autoimmune hepatitis and Evans syndrome complicated with increased expression of TGF-β in the bone marrow: a case report

We here report a 47-year-old female with autoimmune myelofibrosis (AIMF) associated with liver damage caused by autoimmune hepatitis and Evans syndrome. Bone marrow biopsy revealed hypocellular marrow with grade 2 reticulin fibrosis and increased levels of B lymphocytes (CD20 + ), T lymphocytes (CD3...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2017-11, Vol.106 (5), p.718-724
Main Authors: Ohkawara, Hiroshi, Furukawa, Miki, Ikeda, Kazuhiko, Shichishima-Nakamura, Akiko, Fukatsu, Masahiko, Sano, Takahiro, Ueda, Koki, Kimura, Satoshi, Kanai, Risa, Oka, Yuka, Murakami, Fumi, Suzuki, Osamu, Hashimoto, Yuko, Ogawa, Kazuei, Ikezoe, Takayuki
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We here report a 47-year-old female with autoimmune myelofibrosis (AIMF) associated with liver damage caused by autoimmune hepatitis and Evans syndrome. Bone marrow biopsy revealed hypocellular marrow with grade 2 reticulin fibrosis and increased levels of B lymphocytes (CD20 + ), T lymphocytes (CD3 + , CD8 + ), and plasma cells (CD138 + ). Immunohistochemical analysis revealed increased expression of transforming growth factor-β (TGF-β) in infiltrating lymphocytes and macrophages in the bone marrow. She was initially treated with oral prednisolone (PSL) for 2 months, which had a limited effect. However, after treatment with rituximab, the patient’s pancytopenia showed improvement, allowing us to rapidly reduce the PSL dosage. The present case suggests the possibility that increased expression of TGF-β in infiltrating lymphocytes and macrophages of bone marrow may contribute to the pathogenesis of AIMF. Prednisolone combined with rituximab may thus be an effective option for steroid-refractory cases.
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-017-2268-3